ID24735A - Konjugat-konjugat yang berguna pada pengobatan kanker prostat - Google Patents

Konjugat-konjugat yang berguna pada pengobatan kanker prostat

Info

Publication number
ID24735A
ID24735A IDW20001039A ID20001039A ID24735A ID 24735 A ID24735 A ID 24735A ID W20001039 A IDW20001039 A ID W20001039A ID 20001039 A ID20001039 A ID 20001039A ID 24735 A ID24735 A ID 24735A
Authority
ID
Indonesia
Prior art keywords
consequences
useful
treatment
prostate cancer
prostate
Prior art date
Application number
IDW20001039A
Other languages
English (en)
Indonesian (id)
Inventor
Stephen F Brady
Feng Dong-Mei
Victor M Garsky
Original Assignee
Merck & Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9804399.5A external-priority patent/GB9804399D0/en
Application filed by Merck & Co Ltd filed Critical Merck & Co Ltd
Publication of ID24735A publication Critical patent/ID24735A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
IDW20001039A 1997-12-02 1998-11-25 Konjugat-konjugat yang berguna pada pengobatan kanker prostat ID24735A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6711097P 1997-12-02 1997-12-02
GBGB9804399.5A GB9804399D0 (en) 1998-03-02 1998-03-02 Conjugates useful in the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
ID24735A true ID24735A (id) 2000-08-03

Family

ID=26313204

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001039A ID24735A (id) 1997-12-02 1998-11-25 Konjugat-konjugat yang berguna pada pengobatan kanker prostat

Country Status (26)

Country Link
US (2) US20060148718A1 (fr)
EP (1) EP1036093A1 (fr)
JP (1) JP2001525337A (fr)
KR (1) KR100580137B1 (fr)
CN (1) CN1181092C (fr)
AR (1) AR016427A1 (fr)
AU (1) AU744652B2 (fr)
BG (1) BG65486B1 (fr)
BR (1) BR9815116A (fr)
CA (1) CA2311615A1 (fr)
DZ (1) DZ2665A1 (fr)
EA (1) EA002745B1 (fr)
EE (1) EE200000333A (fr)
HR (1) HRP20000367A2 (fr)
HU (1) HUP0100350A3 (fr)
ID (1) ID24735A (fr)
IL (1) IL136167A0 (fr)
IS (1) IS5502A (fr)
NO (1) NO20002804L (fr)
NZ (1) NZ504615A (fr)
PE (1) PE20000009A1 (fr)
PL (1) PL197006B1 (fr)
SK (1) SK8282000A3 (fr)
TR (1) TR200002260T2 (fr)
TW (1) TW577897B (fr)
WO (1) WO1999028345A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1144011T3 (da) * 1998-12-11 2010-07-05 Coulter Pharm Inc Pro-drug-forbindelser og fremgangsmåde til fremstilling deraf
GB9924759D0 (en) * 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
US7842581B2 (en) 2003-03-27 2010-11-30 Samsung Electronics Co., Ltd. Methods of forming metal layers using oxygen gas as a reaction source and methods of fabricating capacitors using such metal layers
JP2010536790A (ja) 2007-08-17 2010-12-02 パーデュー・リサーチ・ファウンデーション Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CN104955484B (zh) * 2012-08-15 2019-01-15 文森医学公司 用于***癌成像的***特异性抗原药剂及其使用方法
AU2013341711A1 (en) * 2012-11-12 2015-05-21 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
BR112015011118B1 (pt) 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
WO2014178839A1 (fr) 2013-04-30 2014-11-06 Hewlett-Packard Development Company, L.P. Vitesse d'accès à une mémoire
TN2016000137A1 (en) 2013-10-18 2017-10-06 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer.
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
CA3203072A1 (fr) 2020-12-22 2022-06-30 Andrea CASAZZA Composes comprenant une fraction tetrapeptidique
WO2022167664A1 (fr) 2021-02-07 2022-08-11 Cobiores Nv Composés comprenant une fraction tétrapeptidique

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4719312A (en) * 1978-10-02 1988-01-12 Merck & Co., Inc. Lysosometropic detergent therapeutic agents
US4376765A (en) * 1980-03-31 1983-03-15 Institut International De Pathologie Cellulaire Et Moleculaire Medicaments, their preparation and compositions containing same
US4639456A (en) * 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
ATE64396T1 (de) * 1983-04-29 1991-06-15 Omnichem Sa Konjugierte vinblastin-verbindungen und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
EP0647450A1 (fr) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Prodrogues améliorées pour activation médiée par enzyme
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
EP0855910A4 (fr) * 1995-10-18 2000-07-05 Merck & Co Inc Conjugues utiles pour traiter l'adenome prostatique benin
JP2001501601A (ja) * 1996-09-12 2001-02-06 メルク エンド カンパニー インコーポレーテッド 前立腺ガンの治療において有用な共役体
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser

Also Published As

Publication number Publication date
BG65486B1 (bg) 2008-09-30
EA002745B1 (ru) 2002-08-29
NO20002804D0 (no) 2000-05-31
EE200000333A (et) 2001-08-15
AU744652B2 (en) 2002-02-28
AR016427A1 (es) 2001-07-04
HUP0100350A2 (hu) 2001-08-28
HRP20000367A2 (en) 2000-12-31
NZ504615A (en) 2003-05-30
IL136167A0 (en) 2001-05-20
US20070021350A1 (en) 2007-01-25
BG104563A (en) 2001-04-30
BR9815116A (pt) 2000-10-10
JP2001525337A (ja) 2001-12-11
PL197006B1 (pl) 2008-02-29
US20060148718A1 (en) 2006-07-06
TW577897B (en) 2004-03-01
TR200002260T2 (tr) 2000-12-21
CN1181092C (zh) 2004-12-22
IS5502A (is) 2000-05-19
KR100580137B1 (ko) 2006-05-16
DZ2665A1 (fr) 2003-03-22
PL340768A1 (en) 2001-02-26
PE20000009A1 (es) 2000-01-27
CA2311615A1 (fr) 1999-06-10
WO1999028345A1 (fr) 1999-06-10
EP1036093A1 (fr) 2000-09-20
SK8282000A3 (en) 2000-11-07
CN1284086A (zh) 2001-02-14
KR20010032687A (ko) 2001-04-25
NO20002804L (no) 2000-07-21
EA200000603A1 (ru) 2000-12-25
AU1612399A (en) 1999-06-16
HUP0100350A3 (en) 2001-09-28

Similar Documents

Publication Publication Date Title
ID21358A (id) Konjugat yang berguna dalam pengobatan kanker prostat
GB9903841D0 (en) Diagnosis and treatment of cancer
IL189132A0 (en) Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer
ID24735A (id) Konjugat-konjugat yang berguna pada pengobatan kanker prostat
NO991701D0 (no) HIV og cancer behandling
HUP0004326A3 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
EP1320376A4 (fr) Traitement du cancer de la prostate
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
NO20002189D0 (no) Anvendelse av makrolider for behandling av cancer og mukuladegenerasjon
PT1117363E (pt) Vibromassajador para alívio de sofrimento e dores
IL147748A0 (en) Use of etodolac to treat cancer
DE69836209D1 (de) Vorbeugung und behandlunhg des hepatozellulären krebses
GB9811598D0 (en) Diagnosis and treatment of cancer
EP0907720A4 (fr) Radiotherapie et immunotherapie combinees pour le traitement du cancer
IL149281A0 (en) Treatment of cancer
NO961113D0 (no) Behandling og forebyggelse av prostatakreft
GB9819999D0 (en) Treatment of cancer
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
GB2343629B (en) Treatment of cellulite
AUPO851597A0 (en) Treatment of prostate cancer
DE29702126U1 (de) Therapie- und Behandlungskabine
AU8719298A (en) Treatment of prostate cancer
HK1079709A1 (zh) 脫唾液酸-干擾素系及肝癌的治療
GB9617941D0 (en) New approach to the treatment of prostate cancer
GB9717401D0 (en) Treatment of psoriasis